logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis | Journal Article / Letter | MSF Science Portal
Journal Article
|Letter

Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis

Mohr E, Ferlazzo G, Hewison CCH, De Azevedo V, Isaakidis P
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
Here we report on the final outcomes for the cohort of 28 patients from Armenia, India, and South Africa who initiated regimens containing the combination of bedaquiline and delamanid from January to August, 2016, for the treatment of multidrug-resistant tuberculosis in our cohort study.1 The median duration on combination treatment was 12 months (interquartile range [IQR] 5·9–20·0); 17 (61%) of 28 patients received the combination for more than 6 months.

Countries

Armenia South Africa India

Subject Area

tuberculosis

Languages

English
DOI
10.1016/S1473-3099(19)30168-9
Published Date
01 May 2019
Journal
Lancet Infectious Diseases
Volume | Issue | Pages
Volume 19
Dimensions Badge